Melanoma & Skin Cancer

Starting the discussion on cutaneous squamous cell carcinoma, Dr Emerick provides insight on signs to look for, as well as risk factors.

Two experts provide their thoughts on phase 2 data concerning the use of cemiplimab for treating locally advanced basal cell carcinoma.

Filip Janku, MD, PhD, discusses the phase 1 study with ripretinib in patients with KIT-mutated or KIT-amplified melanoma.

The FDA has approved pembrolizumab for the adjuvant treatment of adult and pediatric patients with stage IIB or IIC melanoma following complete resection.

Richard D. Carvajal, MD, discusses the need for additional treatment options in patients with rare melanomas, the promise of tebentafusp, and ongoing trials in the pipeline for this patient population.

Jason J. Luke, MD, FACP, discusses the toxicities with targeted therapy vs immunotherapy and management strategies for patients with melanoma. 

The addition of BO-112 to pembrolizumab produced clinical benefit in patients with unresectable malignant melanoma who have experienced disease progression on anti–PD-1 therapy, according to data from the preliminary analysis of the phase 2 SPOTLIGHT-203 trial.

Ezra Cohen, MD, FRCPSC, FASCO, and Gino K. In, MD, MPH, elaborate on the role hedgehog inhibitors can play when treating patients with basal cell carcinoma.

Drs Emerick and Bakst continue to speak on the data from the first clinical case scenario and highlight other treatment options.

Several leading experts discussed a variety of tumor types set to influence the next wave of investigative directions and change the standard of care for patients in abstracts at the European Society for Medical Oncology Congress 2021.

Positive data readouts from studies such as the phase 2/3 RELATIVITY-047 trial with relatlimab and nivolumab, and the phase 3 KEYNOTE-716 trial with pembrolizumab, cemented 2021 as a banner year for the treatment of patients with melanoma, across various stages and subtypes.

Iván Márquez Rodas, MD, PhD, discusses the preliminary results of the phase 2 SPOTLIGHT203 trial, which is evaluating the efficacy and safety of BO-112 plus pembrolizumab in patients with advanced melanoma.

Richard Bakst, MD, and Ezra Cohen, MD, FRCPSC, FASCO, explain what the typical clinical presentation of basal cell carcinoma will look like in a patient.

Kevin Emerick, MD, analyzes the data from the first clinical case scenario and touches upon potential surgical options for patients with similar diagnoses.

Caroline Nebhan, MD, PhD, discusses the efficacy of checkpoint inhibitors in older patients with cancer.

The COVID-19 vaccine was safe and well tolerated in patients who received immune checkpoint inhibitors for renal cell carcinoma or melanoma.

The FDA has greenlit an investigation new drug application to expand the ongoing phase 1/2 ABILITY trial, which is evaluating the beta-only IL-2 superagonist MDNA11 in patients with solid tumors, to clinical trial sites in the United States.

The addition of immune checkpoint inhibitors and targeted therapies has paved the way for advances in the adjuvant and met-astatic setting with recent data from clinical trials demonstrating significant improvements in overall survival for patients with advanced melanoma.

Although there has been dramatic progress in the treatment landscape for metastatic melanoma over the past decade, many patients whose tumors harbor NRAS mutations have not shared in the improved outcomes.

Adjuvant pembrolizumab continued to showcase improved relapse-free survival over placebo in patients with resected high-risk stage II melanoma with 6 months of additional follow-up.

Dirk Schadendorf, MD, discusses expected toxicities with the combination of encorafenib, binimetinib, and pembrolizumab in BRAF V600E/K-mutated melanoma.

Alexander J. Stratigos, MD, PhD, discussed the effect cemiplimab will have on the treatment landscape of patients with advanced BCC.

The FDA has granted a fast track designation to the universal cancer vaccine UV1 for use in combination with checkpoint inhibitors in patients with unresectable or metastatic melanoma, either as an add-on therapy to pembrolizumab or to ipilimumab.

A linear correlation between magnitude of circulating tumor DNA reduction and improved overall survival was observed in patients with metastatic uveal melanoma who were treated with tebentafusp, suggesting that ctDNA may be a better surrogate end point for OS compared with RECIST response criteria.

The European Medicines Agency has validated its marketing authorization application for the fixed-dose combination of relatlimab and nivolumab in the frontline treatment of adult and pediatric patients with advanced melanoma.